Organization: Cellpep SA

Ambrilia inks major licensing deal with Merck

Montreal’s Ambrilia Biopharma Inc has entered a licensing agreement with Merck & Co Inc for worldwide rights to its HIV/AIDS protease inhibitor program. The deal will see Ambrilia receive US$17 million in an upfront licensing fee with payments of up to $215 million if it completes specified development, clinical, regulatory and sales milestones, as well…